Primary mediastinal Castleman's disease

Regal, Mohamed; Aljehani, Yasser; Bousbait, Hanan

doi:10.4081/rt.2010.e11

Cited by 9 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On histological examination, it is usually divided into the hyalinized vascular type and the plasma cell variant type, the latter being more common in the multicentric type of the disease. There also exists a mixed variant [ 6 , 7 ]. Unicentric Castleman’s disease usually presents in early adulthood with localized masses in the mediastinum, rarely causing systemic symptoms.…”

Section: Discussionmentioning

confidence: 99%

Castleman’s disease and sarcoidosis, a rare association resulting in a “mixed” response: a case report

Mohammed

Janků

et al. 2015

J Med Case Reports

View full text Add to dashboard Cite

IntroductionMulticentric Castleman’s disease is a rare lymphoproliferative disorder whose hallmark is atypical lymph node hyperplasia. Symptoms can include fever, splenomegaly, and abnormal blood cell counts. High levels of interleukin 6 (IL-6) are observed frequently in this disorder and are believed to drive the disease. Recently, therapies that target interleukin-6 or its receptor have been shown to be effective in Castleman’s disease.Case presentationWe report the case of a 76-year-old Caucasian man with aggressive biopsy-proven Castleman’s disease who experienced pulmonary and lymph node involvement, as well as fever and weight loss. He was treated with siltuximab, a chimeric anti-interleukin-6 antibody. After 5 months, fluorodeoxyglucose positron emission tomography computed tomography scans showed marked improvement in his lungs, but worsening mediastinal disease, consistent with a mixed response. Biopsy of the mediastinal disease revealed lymphoplasmacytic infiltrate with non-caseating, ill-defined granulomas and scarring consistent with sarcoidosis. Prednisone 50mg by mouth daily was started, which was tapered to 2.0-5.0mg daily. Siltuximab was continued. A subsequent fluorodeoxyglucose positron emission tomography computed tomography scan showed near-complete resolution of lung and mediastinal disease, now ongoing for 3.5+ years without serious adverse events.ConclusionsLymphomas have previously been reported to coexist with sarcoidosis, albeit rarely, but there has been only a single previous case of this type with Castleman’s disease. Of importance, early recognition of the presence of sarcoidosis in our patient prevented discontinuation of siltuximab therapy due to “progression”. Our experience may also have broader implications in that it suggests that etiology of “mixed responses” should be confirmed by performing biopsies on the progressive tumor.

show abstract

Section: Discussionmentioning

confidence: 99%

Castleman’s disease and sarcoidosis, a rare association resulting in a “mixed” response: a case report

Mohammed

Janků

et al. 2015

J Med Case Reports

View full text Add to dashboard Cite

show abstract

“…En la forma multicéntrica, es difícil hablar de tratamiento ideal, dado el escaso número de pacientes de las series publicadas y la amplia variabilidad de los resultados descritos en la literatura. Está recomendado el screening en los casos diagnosticados para confirmar enfermedad localizada o sistémica 10,11 . El seguimiento a largo plazo y la vigilancia periódica aún no están definidos para ninguna de las formas clínicas 1,2 .…”

Section: Discussionunclassified

Enfermedad de Castleman, un diagnóstico diferencial que no se debe olvidar en los tumores de mediastino: Caso clínico

J¹,

Tapia²,

C³

2014

Rev. méd. Chile

View full text Add to dashboard Cite

“…CD is a benign lymphoproliferative disorder [ 1 – 6 ]. It is variously named as angiofollicular hyperplasia, giant lymph node hyperplasia, angiomatous lymphoid hyperplasia, localized nodal hyperplasia, and lymphoid hamartoma [ 3 , 5 ]. CD has a wide age distribution ranging from adolescence to seven decades [ 1 – 3 ].…”

Section: Discussionmentioning

confidence: 99%

“…It is characterized by benign and massive proliferation of lymphoid tissue [1, 3]. Three histologic variants of CD are recognized; hyaline-vascular type (75–90%), plasma cell type (10–25%) and mixed type (1–4%) [1, 4].…”

Section: Introductionmentioning

confidence: 99%

“…Castleman's disease (CD) is first described by Castleman in 1956 in a mediastinal lymph node [ 1 , 2 ]. It is characterized by benign and massive proliferation of lymphoid tissue [ 1 , 3 ]. Three histologic variants of CD are recognized; hyaline-vascular type (75–90%), plasma cell type (10–25%) and mixed type (1–4%) [ 1 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Osseous Metaplasia in Castleman's Disease: A Case Report

Mokhtari

Kumar

2012

Case Reports in Medicine

View full text Add to dashboard Cite

Background. Castleman's disease is a benign lymphoproliferative disorder. The disease may be localized or multicentric. Three histologic variants are recognized: hyaline vascular, plasma cell, and mixed types. Case. A 20-year-old man presented with large left axillary mass. The histologic examination of the resected mass showed follicular pattern with large nodules of mantle cells arranged concentrically around atrophic and vascularized germinal centers. There was also some benign-appearing bone trabeculae interspersed with lymphoid tissue. The diagnosis of Castleman's disease, hyaline-vascular type with osseous metaplasia, was made.

show abstract

Primary mediastinal Castleman's disease

Cited by 9 publications

References 9 publications

Castleman’s disease and sarcoidosis, a rare association resulting in a “mixed” response: a case report

Castleman’s disease and sarcoidosis, a rare association resulting in a “mixed” response: a case report

Enfermedad de Castleman, un diagnóstico diferencial que no se debe olvidar en los tumores de mediastino: Caso clínico

Osseous Metaplasia in Castleman's Disease: A Case Report

Contact Info

Product

Resources

About